NCT03478462
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03478462
Title Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas (CLOVER-2)
Acronym CLOVER-2
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cellectar Biosciences, Inc.
Indications
Therapies
Age Groups: adult | child
Covered Countries USA | CAN | AUS


No variant requirements are available.